Business Wire

ExOne Showcases Ability to 3D Print Virtually Any Powder Material in New Corporate Video, “Let’s Make it Right”

20.10.2021 15:30:00 EEST | Business Wire | Press release

Share

The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced that it is open to developing virtually any powder material in partnership with manufacturers for their specific application.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005203/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The ExOne Company has released a new corporate video, "Let's Make it Right," showcasing the ability of its sustainable binder jetting technology to 3D print virtually any type of powder. ExOne has already qualified more than 20 metals, ceramics and composites for 3D printing, but is now developing materials such as pulverized concrete and other waste products with customers. (Photo: Business Wire)

The material flexibility and sustainability of ExOne’s patented binder jet 3D printing technology is showcased in a new corporate video unveiled today, “Let’s Make it Right.” The video is a celebration of ExOne’s employees and their accomplishments over more than 20 years as the company prepares to be acquired by Desktop Metal.

Beginning in the mid-1990s, ExOne pioneered the commercial development of MIT’s patented binder jet 3D printing process, which transforms powdered materials into precision parts or tooling at high speeds. An industrial printhead selectively deposits binder into a bed of powder particles creating a solid part one layer at a time, just like printing on sheets of paper.

The company’s RTS-300, launched in 1998, was the first commercially available metal binder jet system. ExOne later began binder jetting sand for metalcasting molds and cores. Today, ExOne has a portfolio of eight sand and metal 3D printing systems that can print a wide range of powders into highly dense parts, or even parts with controlled porosity, for specific applications.

“Binder jet 3D printing is one of the few additive manufacturing technologies that holds the promise of being an all-purpose manufacturing tool; it can print just about any powdered material into any form or functional purpose. In recent years, advancements in machine design and binder chemistries have helped us take a leap closer to that ultimate goal,” said Rick Lucas, ExOne Chief Technology Officer and VP of New Markets. “We are thankful to all of our former and current employees, as well as our R&D partners around the world, who have helped us advance binder jetting to where it is today and continue to support development efforts around this important green technology.”

Unique Material Flexibility in 3D Printing

Binder jetting is viewed as a desirable and sustainable production method, largely because of its high speed, low waste and cost, as well as broad material flexibility, which is just beginning to be untapped because of ExOne’s improvements in machine design and binder chemistries.

To achieve high-density parts, such as metals, the printed part is typically sintered in a furnace to fuse the particles together into a high-density solid object. Porous parts, often created with sand or other large-particle media, can also be infiltrated with resins or metals to achieve desired properties and create unique composites.

Two new case studies illustrate the broad range of ExOne’s binder jetting technology beyond traditional industrial applications:

  • Luxury sound system company, Deeptime, manufactures its speakers with 3D printed sand that is infiltrated with a proprietary solution to deliver material properties that are 86% more rigid than MDF, leading to double the sound damping compared to traditional speakers and much higher performance.
  • Carnegie Mellon University’s School of Architecture, meanwhile, is developing binder jetting of pulverized concrete and other recycled materials that are then infiltrated with resins for use as durable outdoor architectural pieces. This approach represents the future of cradle-to-grave, ecologically intelligent building design.

ExOne’s resin-infiltrated sand 3D printing for architectural restoration was a finalist in the 2021 Awards for Composites Excellence at CAMX, the Composites and Advanced Materials Expo.

Full Flexibility of Binder Jet 3D Printing

Among the broad categories of materials that ExOne can now develop to manufacturer specifications:

  • Aluminum alloys
  • Carbides
  • Copper and copper alloys
  • Nickel alloys
  • Nitrides
  • Oxides
  • Precious metal alloys, including silver and gold
  • Refractory metals, such as tungsten and molybdenum alloys
  • Sands
  • Stainless steels, such as 17-4PH, 316L and 304L
  • Titanium alloys, such as Ti64
  • Tool steels, such as M2 and H13
  • Waste products such as concrete and more

ExOne’s new corporate video is available at www.exone.com/MakeitRight.

About ExOne

ExOne (Nasdaq: XONE) is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sarah Webster
Chief Marketing Officer
724.516.2336
sarah.webster@exone.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye